Business Context and Reporting Period
This Form 8-K Current Report was filed by Brucker Corporation on November 11, 2015. The filing reports a corporate governance event regarding the expansion of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors approved an increase in the number of directors from thirteen to fourteen.
- New Appointment: Dr. Robert Rosenthal was elected to fill the newly created vacancy in Class I, effective immediately.
- Term: Dr. Rosenthal's term expires at the Company's 2016 Annual Meeting of Stockholders.
Management Commentary and Background
Dr. Rosenthal brings significant experience in the life sciences and medical technology sectors. His background includes:
- Current CEO of Taconic Biosciences, Inc. (since June 2014).
- Former President and CEO of IMI Intelligent Medical Implants, AG (2010–2012) and Magellan Biosciences, Inc. (2005–2009).
- Previous senior management roles at Perkin Elmer Inc. and Thermo Fisher Scientific, Inc.
- Current director roles at Safeguard Scientifics, Inc., Taconic Biosciences, and Galvanic Applied Sciences, Inc.
Dr. Rosenthal's compensation will be consistent with other non-employee directors as described in the 2015 proxy statement. No other arrangements or transactions requiring disclosure under Item 404(a) of Regulation S-K exist.
Investor Verification Checklist
- Verify the total number of directors on the Board is now fourteen.
- Confirm Dr. Rosenthal's term expiration date aligns with the 2016 Annual Meeting of Stockholders.
- Review the attached press release (Exhibit 99.1) for additional details on the appointment.
- Check the 2015 proxy statement for specific director compensation details applicable to Dr. Rosenthal.